OncoMatch/Clinical Trials/NCT03842943
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Is NCT03842943 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Talimogene Laherparepvec for cutaneous melanoma.
Treatment: Pembrolizumab · Talimogene Laherparepvec — Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF mutation or wild-type allowed
BRAF mutant or wild type allowed (mutations status not necessary for enrollment)
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncolytic virus (T-VEC)
May not have been previously treated with T-VEC, any other oncolytic virus
Cannot have received: anti-PD-1 therapy (pembrolizumab)
May not have been previously treated with pembrolizumab, or any other PD-1, PD-L1, or PD-L2 inhibitor
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Louisville · Louisville, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03842943 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior oncolytic virus, anti-PD-1 therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages